A multidisciplinary research team has found a new use for a reliable medical device. Multiple heart patients have already benefited for the group’s outside-the-box thinking.
The high-risk patients who require urgent or emergent TAVR are often excluded from major clinical trials. To learn more about this population, researchers explored data from nearly 600 patients treated at high-volume facilities.
Regulators recently scolded the France-based pharmaceutical firm for safety issues that occurred at its plant in Raleigh, North Carolina, which produces imaging contrast agents.
Sophia Shaklian, 38, of Los Angeles, and accomplices bilked Medicare of millions by submitting false claims for diagnostic imaging and hospice care that was unnecessary or never administered.
Dana Smetherman, MD, CEO of the ACR, explains a resolution adopted at the American Medical Association House of Delegates meeting calling for new health IT standards.
The agent “exhibits powerful tumor delineation” in challenging cases of determining cancer subtypes, and could potentially lead to more personalized, effective treatment strategies.
The device covers three vessels at once and can be deployed through the patient's TAVR access site. Researchers shared their first-in-human experience in JACC: Case Reports.
A multidisciplinary research team has found a new use for a reliable medical device. Multiple heart patients have already benefited for the group’s outside-the-box thinking.
